Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Post-HCT azithromycin doesn’t increase relapse risk, study suggests

Key clinical point: When given after transplant, azithromycin does not increase the risk of relapse in patients with moderate to severe chronic graft-versus-host disease and bronchiolitis obliterans syndrome, according to a retrospective study.

Major finding: The 2-year relapse rate was significantly lower in patients who received azithromycin than in those who did not – 4% and 17%, respectively (P = .001).

Study details: A retrospective study of 239 patients

Disclosures: The speaker reported no conflicts of interest.


Shamoun M et al. TCT 2019, Abstract 33.